AI-generated from publicly available materials.Clarivate has announced the enhancement of its agentic AI capabilities within the Cortellis portfolio, aimed at streamlining drug development processes for life sciences organizations.
This expansion allows research and development teams to leverage AI to accelerate discovery, improve safety assessments, and make informed decisions throughout the drug development lifecycle. By integrating AI into existing workflows, researchers can minimize manual tasks and concentrate on strategic scientific decisions, ultimately leading to more efficient outcomes.
Key advancements include enhanced features in Cortellis Drug Discovery Intelligence, which facilitate natural language interactions with complex drug data, enabling quicker evaluations of therapeutic landscapes and prioritization of opportunities. Additionally, OFF-X now employs multi-agent intelligence to identify potential safety liabilities earlier in the development process, thereby enhancing risk assessment capabilities. Furthermore, Cortellis Competitive Intelligence has introduced new workflows that transform extensive manual analyses into actionable insights in a fraction of the time.
The implications of these developments are significant, as they represent a shift from traditional data delivery to a more integrated approach that supports decision-making in high-stakes environments. This evolution reflects the increasing importance of AI in life sciences, where rapid and informed actions can lead to competitive advantages in drug development.